Cellectis S.A. (NASDAQ:CLLS) Stock Has Average Target Price of $5.46 According to Brokerages

Shares of Cellectis S.A. (NASDAQ:CLLS) have received a consensus recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $5.46.

A number of research analysts have recently weighed in on the company. Citizens Jmp reissued a “market perform” rating on shares of Cellectis in a report on Tuesday, September 15th. Robert W. Baird decreased their target price on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, September 15th. Wells Fargo & Company dropped their target price on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, September 15th. Barclays lowered Cellectis from an “overweight” rating to an “underweight” rating and dropped their target price for the company from $9.00 to $1.30 in a research report on Wednesday, September 16th. Finally, Weiss Ratings upgraded shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd.

Institutional Trading of Cellectis

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC acquired a new position in Cellectis S.A. (NASDAQ:CLLS) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Stock Performance

Shares of CLLS opened at $0.98 on Friday. Cellectis has a 12 month low of $0.88 and a 12 month high of $5.45. The firm has a market cap of $98.33 million, a PE ratio of -1.51 and a beta of 3.00. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The stock has a fifty day moving average price of $2.10 and a 200-day moving average price of $2.89.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%. The company had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million.

Cellectis Company Profile

Cellectis SA is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments.

The company’s primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.